{"id":478,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2020-12-11","marketCap":4.2498860359191895,"name":"Vivos Therapeutics Inc","phone":"18669084867.0","outstanding":1.2000000476837158,"symbol":"VVOS","website":"https://vivos.com/","industry":"Health Care"},"price":3.5065,"year":2023,"month":11,"day":7,"weekday":"Tuesday","title":"Competitive Advantages of Vivos Therapeutics Inc","date":"2023-11-07","url":"/posts/2023/11/07/VVOS","content":[{"section":"1. Innovative Treatment Solution","text":"Vivos Therapeutics Inc offers a unique and innovative treatment solution for sleep apnea and other breathing-related sleep disorders. Their proprietary Vivos System utilizes a non-invasive oral appliance that helps to correct and improve the anatomical structures of the upper airway. This approach stands out in the industry as it provides an alternative to traditional CPAP machines and invasive surgeries."},{"section":"2. Extensive Research and Development","text":"Vivos Therapeutics Inc has invested significantly in research and development to continually improve their treatment solutions. They collaborate with leading experts in the field of sleep medicine, dentistry, and orthodontics to advance their understanding of the underlying causes of sleep apnea and develop innovative solutions. This commitment to research sets them apart from their peers and allows them to offer cutting-edge treatment options."},{"section":"3. Comprehensive Training and Support","text":"Vivos Therapeutics Inc provides comprehensive training and support to healthcare professionals who offer their treatment solutions. They offer training programs, resources, and ongoing support to ensure that clinicians are well-equipped to provide the highest standard of care to patients. This focus on training and support enhances the adoption and success of their treatment approach and distinguishes them from competitors."},{"section":"4. Patient-Centric Approach","text":"Vivos Therapeutics Inc places a strong emphasis on the patient experience and satisfaction. They prioritize personalized care and ensure that the treatment plans are tailored to individual needs. Their patient-centric approach includes regular monitoring, adjustments, and ongoing communication with patients to ensure optimal outcomes. This focus on patient well-being sets them apart and fosters loyalty and trust among their customer base."},{"section":"5. Strong Intellectual Property Portfolio","text":"Vivos Therapeutics Inc has built a robust intellectual property portfolio, including patents, trademarks, and proprietary technologies. This intellectual property protection provides a significant competitive advantage, as it prevents competitors from replicating their innovative treatment solutions. The strong intellectual property position strengthens the market position of Vivos Therapeutics Inc and makes it difficult for peers to imitate their success."},{"section":"6. Established Partnerships and Collaborations","text":"Vivos Therapeutics Inc has formed strategic partnerships and collaborations with key industry players and experts. These partnerships enable them to leverage collective expertise, resources, and distribution channels. By collaborating with renowned medical professionals and organizations, they enhance their credibility and reach, setting them apart from competitors who lack such strategic alliances."},{"section":"7. Strong Growth Potential","text":"Vivos Therapeutics Inc operates in a growing market driven by the increasing prevalence of sleep apnea and the demand for effective non-invasive treatment options. With their innovative solutions and comprehensive approach, they are well-positioned to capture a significant share of this expanding market. The company's strong growth potential sets it apart from its industry peers and attracts investors seeking opportunities in the healthcare sector."},{"section":"8. Focus on Evidence-Based Results","text":"Vivos Therapeutics Inc is committed to evidence-based results and clinical validation. They conduct clinical trials and research studies to demonstrate the effectiveness of their treatment solutions and to ensure regulatory compliance. Their focus on evidence-based results provides confidence to healthcare professionals, patients, and investors, differentiating them from competitors who may lack rigorous scientific validation."}],"tags":["CrossOver200","Long","Health Care"],"news":[{"category":"company","date":1699033864,"headline":"Vivos Therapeutics agrees to nationwide distribution deal with in-home respiratory dealer Lincare","id":123602310,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"VVOS","publisher":"Yahoo","summary":"Vivos Therapeutics CEO Kirk Huntsman joined Steve Darling from Proactive to share news the company has signed a nationwide distribution agreement in the United States with Lincare, a prominent supp...","url":"https://finance.yahoo.com/news/vivos-therapeutics-agrees-nationwide-distribution-175104711.html"},{"category":"company","date":1698958800,"headline":"Vivos Therapeutics Closes $4 Million Private Placement","id":123578195,"image":"https://media.zenfs.com/en/globenewswire.com/725d8fbec3d3dd0dfd7f58221775bf79","symbol":"VVOS","publisher":"Yahoo","summary":"LITTLETON, Colo., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults, announced that today it has closed a $4 million private placement previously announced on October 31, 2023. After deducting estimated offering expenses, Vivos expects the net p","url":"https://finance.yahoo.com/news/vivos-therapeutics-closes-4-million-210000412.html"},{"category":"company","date":1698853423,"headline":"Vivos Therapeutics (VVOS) Price Target Increased by 2400.00% to 45.90","id":123546009,"image":"","symbol":"VVOS","publisher":"Fintel","summary":"","url":"https://fintel.io/news/vivos-therapeutics-vvos-price-target-increased-by-240000-to-4590-381"},{"category":"company","date":1698753600,"headline":"Vivos Therapeutics Announces Pricing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules","id":123527576,"image":"https://media.zenfs.com/en/globenewswire.com/725d8fbec3d3dd0dfd7f58221775bf79","symbol":"VVOS","publisher":"Yahoo","summary":"LITTLETON, Colo., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults, today announced that it has entered into a securities purchase agreement with an institutional investor for the purchase and sale of 980,393 shares of its common stock (or pre-","url":"https://finance.yahoo.com/news/vivos-therapeutics-announces-pricing-4-120000773.html"},{"category":"company","date":1698740580,"headline":"Vivos Therapeutics prices $4M public offering","id":123527083,"image":"","symbol":"VVOS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3186969900"},{"category":"company","date":1698736260,"headline":"Vivos Therapeutics sells 980,393 shaes at $4.08 in private placement","id":123527085,"image":"","symbol":"VVOS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3186872083"},{"category":"company","date":1698410880,"headline":"IPA, IMTE and CNTB among mid-day movers","id":123454446,"image":"","symbol":"VVOS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3181679590"},{"category":"company","date":1698409080,"headline":"Why Barnes Group Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Friday's Mid-Day Session","id":123453727,"image":"","symbol":"VVOS","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3181633252"},{"category":"company","date":1698405480,"headline":"Stocks Mixed As Nasdaq Rallies To End The Week","id":123453728,"image":"","symbol":"VVOS","publisher":"TalkMarkets","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3181538638"},{"category":"company","date":1698397740,"headline":"Sanofi, Dexcom among healthcare movers","id":123451701,"image":"","symbol":"VVOS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3181344755"},{"category":"company","date":1698319800,"headline":"Vivos Therapeutics Announces Reverse Stock Split","id":123423576,"image":"https://media.zenfs.com/en/globenewswire.com/725d8fbec3d3dd0dfd7f58221775bf79","symbol":"VVOS","publisher":"Yahoo","summary":"1-for-25 reverse stock split to become effective as of the opening of trading tomorrow, October 27, 2023LITTLETON, Colo., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults, announced that it will effect a 1-for-25 reverse stock split (the “Reverse Stock Split”) of its issued","url":"https://finance.yahoo.com/news/vivos-therapeutics-announces-reverse-stock-113000214.html"},{"category":"company","date":1698312480,"headline":"Vivos Therapeutics announces 1-for-25 reverse stock split","id":123428953,"image":"","symbol":"VVOS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3179238147"},{"category":"company","date":1698302220,"headline":"Vivos Therapeutics  to effect 1-for-25 reverse stock split","id":123428956,"image":"","symbol":"VVOS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3178995804"},{"category":"company","date":1698147000,"headline":"Vivos Therapeutics Signs Nationwide Distribution Agreement with Lincare","id":123367402,"image":"https://media.zenfs.com/en/globenewswire.com/725d8fbec3d3dd0dfd7f58221775bf79","symbol":"VVOS","publisher":"Yahoo","summary":"Lincare to distribute Vivos oral appliances through an exclusive nationwide agreementLITTLETON, Colo., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS a leading medical technology company focused on developing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults, has signed a U.S. nationwide distribution agreement with Lincare, a leading supplier of in-home respiratory therapy pro","url":"https://finance.yahoo.com/news/vivos-therapeutics-signs-nationwide-distribution-113000029.html"},{"category":"company","date":1698135600,"headline":"Vivos Therapeutics, Lincare ink distribution deal","id":123366631,"image":"","symbol":"VVOS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3175143873"},{"category":"company","date":1698134880,"headline":"12 Health Care Stocks Moving In Tuesday's Pre-Market Session","id":123362226,"image":"","symbol":"VVOS","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3175128096"},{"category":"company","date":1698129180,"headline":"Vivos Therapeutics signs distribution agreement with Lincare","id":123366637,"image":"","symbol":"VVOS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3175014628"}]}